The present invention relates generally to a method for performing a coronary artery bypass procedure and, more particularly, to a method for performing an intravascular coronary artery bypass procedure providing a direct flow path from a heart chamber to the coronary artery.
Coronary artery disease (e.g., the accumulation of arteriosclerotic plaque within a coronary artery) is the leading cause of premature death in industrialized societies. Modern medical science has developed several procedures for treating coronary artery disease. For example, one method for treating coronary artery disease involves harvesting a saphenous vein or other venous or arterial conduit from elsewhere in the body, or using an artificial conduit, such as one made of expanded polytetrafluoroethylene (ePTFE) tubing, and connecting this conduit as a bypass graft from a viable artery or a chamber of the heart to the coronary artery downstream of the blockage or narrowing. While such treatments are well-established medical procedures, they are not without shortcomings. For example, the number of bypass conduits available for harvesting from the patient is limited. Furthermore, these procedures typically cause significant tissue damage to the patient at the harvest site as well as at the patient's chest.
In addition to the bypass procedures mentioned above, several intravascular methods exist that allow surgeons to re-open the diseased artery, such as, angioplasty or atherectomy. Angioplasty involves the intravascular introduction of a balloon-equipped catheter into the diseased blood vessel. Once the catheter is guided to the appropriate location, the balloon is inflated compressing the arteriosclerotic plaque against the wall of the blood vessel. Atherectomy results in the physical desolution of plaque within the diseased blood vessel using a catheter equipped with a removal tool (e.g., a cutting blade or high-speed rotating tip). While these procedures are less-invasive and are effective in treating the diseased blood vessel, there are shortcomings with these procedures. For example, many existing intravascular procedures do not allow the surgeon to bypass the obstruction. Instead, separate catheter devices are typically inserted in the patient to achieve, for example, revascularization of the blood vessel at a location downstream from the obstruction.
Improvements in intravascular procedures used for treating coronary artery disease are, therefore, sought.
The present invention relates generally to a method for performing a coronary artery bypass procedure. More particularly, the present invention relates to a method for performing an intravascular coronary artery bypass procedure providing a direct flow path from a heart chamber to the coronary artery. The method of the present disclosure is preferably utilized where the patient's vascular system is used as a conduit for accessing or reaching a desired location within the patient's body.
In one aspect of the disclosure, a method for supplementing a flow of blood to a portion of the cardiovascular system of a patient is disclosed. The method can comprise inserting a catheter device into the vasculature of the patient and advancing the catheter device to a first location within a first coronary vessel within the cardiovascular system; guiding the catheter device through an interstitial passageway formed between the first location and a second location within a second coronary vessel that is distal to an obstruction in the second coronary vessel; forming a blood flow path from a heart chamber directly to the second coronary vessel; and occluding the interstitial passageway between the first coronary vessel and the second coronary vessel to prevent blood flow through the interstitial passageway. In this aspect, the second coronary vessel is a coronary artery, such as, the left anterior descending coronary artery. Similarly, the first coronary vessel is a coronary vein proximate to the coronary artery, such as, the great cardiac vein.
Further to this aspect, forming a blood flow path from the heart chamber directly to the second coronary vessel can include placing a conduit in a heart wall between the heart chamber and the second coronary vessel. Moreover, placing a conduit in a heart wall between the heart chamber and the second coronary vessel can include placing a conduit in a septal passageway extending into the heart wall between the heart chamber and the second coronary vessel.
Still further in this aspect, the interstitial passageway is formed through a wall of the first coronary vessel and through a wall of the second coronary vessel between the first and second locations. In so doing, occluding the interstitial passageway can include deploying an embolization substance at the wall of the first vessel and at the wall of the second vessel. Alternatively, occluding the interstitial passageway includes deploying an embolization device within the interstitial passageway.
In another aspect of the invention, the method can comprise inserting a catheter device into the vasculature of the patient and advancing the catheter device to a first location within a first coronary vessel within the cardiovascular system; guiding the catheter device through a first interstitial passageway formed between the first location and a second location within a second coronary vessel within the cardiovascular system; advancing the catheter device to a third location within the second coronary vessel; guiding the catheter device through a second interstitial passageway formed between the third location and a fourth location within the first coronary vessel that is distal to an obstruction in the first coronary vessel; forming a blood flow path from a heart chamber directly to the first coronary vessel; and occluding the first and second interstitial passageways between the first coronary vessel and the second coronary vessel to prevent blood flow through either of the first or second passageways. In this aspect, the first coronary vessel is a coronary artery, such as, the left anterior descending coronary artery. Similarly, the second coronary vessel is a coronary vein proximate to the coronary artery, such as, the great cardiac vein.
Further to this aspect, forming a blood flow path from the heart chamber directly to the first coronary vessel can include placing a conduit in a heart wall between the heart chamber and the first coronary vessel. Moreover, placing a conduit in a heart wall between the heart chamber and the first coronary vessel can include placing a conduit in a septal passageway extending into the heart wall between the heart chamber and the first coronary vessel.
Still further in this aspect, the first interstitial passageway is formed through a wall of the first coronary vessel and through a wall of the second coronary vessel between the first and second locations. Likewise, the second interstitial passageway is formed through a wall of the second coronary vessel and through a wall of the first coronary vessel between the third and fourth locations. In so doing, occluding the first and second interstitial passageways can include deploying an embolization substance at the wall of the first coronary vessel and at the wall of the second coronary vessel at the first interstitial passageway; and deploying an embolization substance at the wall of the first coronary vessel and at the wall of the second coronary vessel at the second interstitial passageway. Alternatively, occluding the first and second interstitial passageways can include deploying an embolization device within each of the first and second passageways.
In still another aspect of the invention, the method can comprise inserting a catheter device into the vasculature of the patient and advancing the catheter device to a first location within a coronary vessel within the cardiovascular system that is proximate to an obstruction within the coronary vessel; advancing the catheter device through the obstruction to a second position distal to the obstruction; guiding the catheter device through an interstitial passageway extending into a heart wall between a heart chamber and the coronary vessel; and placing a conduit in the interstitial passageway extending into the heart wall between the heart chamber and the coronary vessel. In this aspect, the coronary vessel can be a coronary artery.
Further in this aspect, the method can further comprise distending the obstruction within the coronary vessel. Accordingly, distending the obstruction within the coronary vessel can include inflating a balloon at the obstruction within the coronary vessel. Moreover, the interstitial passageway can include a septal passageway extending into the heart wall between the heart chamber and the coronary vessel.
The invention may be more completely understood in consideration of the following detailed description of various embodiments of the invention in connection with the accompanying drawings, in which:
While the invention is amenable to various modifications and alternative forms, specifics thereof have been shown by way of example in the drawings and will be described in detail. It should be understood, however, that the intention is not to limit the invention to the particular embodiments described. On the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the invention as defined by the appended claims.
Various embodiments of the present invention will be described in detail with reference to the drawings, wherein like reference numerals represent like parts and assemblies throughout the several views. Reference to various embodiments does not limit the scope of the present invention, which is limited only by the scope of the claims attached hereto.
The following discussion is intended to provide a brief, general description of a method of intravascular treatment of a diseased blood vessel within a patient's vascular system. The method of the present disclosure may be implemented during any intravascular surgical procedure where it is desirous to utilize the patient's vascular system as a conduit for accessing or reaching a desired location within the patient's body to effect an appropriate medical intervention.
As will become apparent from the discussion below in connection with the accompanying drawings, the present disclosure has particularized applicability to the treatment of diseased blood vessels within the patient's cardiovascular system. However, it will be appreciated by those having skill in the art that the present disclosure is not limited to the specific embodiments discussed below. Rather, the present disclosure has general applicability to situations where it is desirable to treat a diseased blood vessel by utilizing the patient's vascular system as a conduit for accessing or reaching a desired location within the patient's body.
Moreover, in the most preferred embodiments, the left ventricle is the chamber of the heart utilized. There are two reasons for this selection. First, the left ventricle normally provides blood to the coronary arteries, because it pumps blood into the aorta from which the coronary arteries branch. Therefore, the magnitude of the blood pressure peak generated by the left ventricle is most similar to the blood pressure peak the proximal coronary artery would normally experience. Second, the blood which flows into the left ventricle is returning from the lungs. In the lungs, the blood acquires oxygen and loses carbon dioxide. Thus, the blood available by shunting from the chambers of the left side of the heart will have a higher oxygen and lower carbon dioxide content than blood within the right-side chambers.
Now referring to
As shown in
As shown in
As discussed above, the present disclosure provides a method for utilizing the patient's 100 vascular system as a conduit for accessing or reaching to a desired location with the patient's 100 body. The desired location within the patient's 100 vascular system can be determined through standard radiographic techniques well-known to those having ordinary skill in the art. Once at the desired location (e.g., the treatment zone or diseased portion 113), a surgeon can treat the diseased coronary blood vessel by revascularizing the diseased blood vessel. In particular, the method of the present disclosure provides for the transmycardial revascularization of the diseased blood vessel by establishing a channel leading from a chamber of the patient's 100 heart into the diseased blood vessel. This will be described in greater detail below.
Now referring to
The wall 114 of the first blood vessel 112 (e.g., the coronary artery) defines a lumen 115 that serves to deliver oxygenated blood to the patient's 100 heart muscle (e.g., the myocardium 152). The blood flow through the first blood vessel 112 flows in the direction of arrow A. Moreover, as shown throughout
In accordance with the method of the present disclosure, the catheter device 102 can be advanced within the patient's 100 vascular system to a first location 130 within the first blood vessel 112 (e.g., the coronary artery). In the illustrated embodiment, the first location 130 is situated proximate to the obstruction 122. As discussed above, it is often desirous to treat the diseased blood vessel (e.g., via revascularization or any other suitable technique or medical intervention) by situating the catheter 102 downstream or distal to the obstruction 122. In one possible embodiment, this can be accomplished by diverting the catheter 102 around the obstruction 122. In particular, as will be discussed in connection with
In one possible embodiment, the catheter 102 can be guided to a location distal to the obstruction 122 by being diverted from within the first coronary vessel 112 (e.g., the coronary artery) into the second coronary blood vessel 116 (e.g., the coronary vein). To accomplish this, as shown in
Once the catheter device 102 is positioned within the second coronary vessel 116 (e.g., the coronary vein), the catheter 102 can be guided through the lumen 119 as shown in
While the first and second interstitial passageways 140, 142 are illustrated as having been created substantially perpendicular to the first and second coronary blood vessels 112, 116, it will be appreciated by those having skill in the art that the first and second interstitial passageways 140, 142 can be formed at any angle suitable for providing a path of communication between the first and second coronary vessels 112, 116, thereby, allowing the catheter device 102 to be diverted into or out of either of the coronary blood vessels 112, 116.
As shown in
For example, as shown in
Once the channel 143 is formed, a transmyocardial implant 146 (e.g., a conduit) can be deployed within the channel 143. In certain embodiments, the transmyocardial implant 146 can include a tubular reinforcing structure (e.g., a mesh and/or coild tube, a tube defined by a plurality of circumferential and axial struts/supports, etc.) that is expandable from an undeployed state to a deployed state. In the undeployed state, the transmyocardial implant 146 has a reduce diameter sized for allowing the implant to be directed through the patient's 100 vasculature. In the deployed state, the implant has an expanded diameter sized for allowing the transmyocardial implant 146 to be securely held within the channel 143. The reinforcing structure of the transmyocardial implant 146 can be expanded by known techniques (e.g., the structure can be balloon expandable or self expanding). Additionally, some embodiments of the transmyocardial implant 146 can include a liner for preventing thrombosis as shown in U.S. patent application Ser. No. 09/141,284, filed 27 Aug. 1999, the entire disclosure of which is, hereby, incorporated by reference.
During installation, the transmyocardial implant 146 can be positioned within the channel 143 in its undeployed state. Once properly positioned, the transmyocardial implant 146 can be deployed. In it deployed state, the transmyocardial implant 146 is sized to be retained within the formed channel 143. Moreover, once in place, the transmyocardial implant 146 creates a permanent transmyocardial channel between the heart chamber 150 and the coronary artery 112.
In addition to deployment of the transmyocardial implant 146, the first and second interstitial passageways 140, 142 can be blocked or occluded to prevent blood flow through the first and second interstitial passageways 140, 142. In so doing, the method of the present disclosure restores and/or ensures normal coronary aterial and veinous blood flow. To accomplish this, one or more embolization devices can be deployed within each of the first and second interstitial passageways 140, 142. In the embodiment illustrated in
An alternative method for treating a diseased blood vessel by utilizing the patient's 100 vascular system as a conduit for accessing or reaching a desired location within the patient's body will now be described in connection with
Once at the first location 130′, the catheter 102 can be diverted from within the second coronary blood vessel 116 such that it returns to the first coronary vessel 112. In particular, as shown in FIG. 3B and as discussed above, the catheter device 102 can be equipped with (or used in conjunction with a catheter equipped with) an ablation device, for example, an ablation tip (not shown) capable of ablating or otherwise creating an interstitial passageway or channel 140′ between the second coronary vessel 116 and the first coronary vessel 112. The second interstitial passageway 142 provides a path of communication between the second coronary vessel 116 and the first coronary vessel 112 distal to the obstruction 122. In one possible embodiment, the interstitial passageway 140′ is formed through the wall 118 of the second coronary vessel 116 and through the wall 114 of the first coronary vessel 112 between the first location 130′ and a second location 132′ within the first coronary vessel 112. Once the interstitial passageway 142 has been formed, the catheter device 102 can be guided over the guide wire 103 into the first coronary vessel 112.
While the interstitial passageway 140′ is illustrated as having been created substantially perpendicular to the first and second coronary blood vessels 112, 116, it will be appreciated by those having skill in the art that the interstitial passageway 140′ can be formed at any angle suitable for providing a path of communication between the first and second coronary vessels 112, 116, thereby, allowing the catheter device 102 to be diverted into or out of either of the coronary blood vessels 112, 116.
As shown in
Once the channel 143′ is formed, a transmyocardial implant 146′ (e.g., a conduit) can be deployed within the channel 143′. In certain embodiments, the transmyocardial implant 146′ can include a tubular reinforcing structure (e.g., a mesh and/or coild tube, a tube defined by a plurality of circumferential and axial struts/supports, etc.) that is expandable from an undeployed state to a deployed state. In the undeployed state, the transmyocardial implant 146′ has a reduce diameter sized for allowing the implant to be directed through the patient's 100 vasculature. In the deployed state, the implant has an expanded diameter sized for allowing the transmyocardial implant 146′ to be securely held within the channel 143′. The reinforcing structure of the transmyocardial implant 146′ can be expanded by known techniques (e.g., the structure can be balloon expandable or self expanding) and can include a liner for preventing thrombosis as discussed above.
During installation, the transmyocardial implant 146′ can be positioned within the channel 143′ in its undeployed state. Once properly positioned, the transmyocardial implant 146′ can be deployed. In it deployed state, the transmyocardial implant 146′ is sized to be retained within the formed channel 143′. Moreover, once in place, the transmyocardial implant 146′ creates a permanent transmyocardial channel between the heart chamber 150 and the coronary artery 112.
In addition to deployment of the transmyocardial implant 146′, the interstitial passageway 140′ can be blocked to restore and/or ensure normal coronary aterial and veinous blood flow. To accomplish this, one or more embolization devices can be deployed within the interstitial passageways 140′. In the embodiment illustrated in
Still yet another possible method for treating a diseased blood vessel by utilizing the patient's 100 vascular system as a conduit for accessing or reaching a desired location within the patient's body will now be described in connection with
As shown in
Once the catheter 102 is situated at the second location 132″ within the first coronary vessel 112 (e.g., the coronary artery), a channel can be established between the heart chamber 150 and the first coronary vessel 112. In the particular embodiment illustrated in
In situations where an existing opening is used, such as, the septal branches 160, 162, the pathway to the heart chamber 150 must be extended to establish communication with the heart chamber 150. For example, as shown in
As shown in FIG. 4E and as discussed above, once the channel 165 is formed, a transmyocardial implant 166 can be deployed in the channel 165. Additionally, a stent forming device 168 can be deployed within the first coronary blood vessel 112 adjacent to the channel 165. As can be seen in
The various embodiments described above are provided by way of illustration only and should not be construed to limit the invention. Those skilled in the art will readily recognize the various modifications and changes which may be made to the present invention without strictly following the exemplary embodiments illustrated and described herein, and without departing from the true spirit and scope of the present invention, which is set forth in the following claims.
Number | Name | Date | Kind |
---|---|---|---|
4953553 | Tremulis | Sep 1990 | A |
5193546 | Shaknovich | Mar 1993 | A |
5254113 | Wilk | Oct 1993 | A |
5258008 | Wilk | Nov 1993 | A |
5287861 | Wilk | Feb 1994 | A |
5330486 | Wilk | Jul 1994 | A |
5344426 | Lau et al. | Sep 1994 | A |
5385528 | Wilk | Jan 1995 | A |
5389096 | Aita et al. | Feb 1995 | A |
5409019 | Wilk | Apr 1995 | A |
5425757 | Tiefenbrun et al. | Jun 1995 | A |
5425765 | Tiefenbrun et al. | Jun 1995 | A |
5429144 | Wilk | Jul 1995 | A |
5470320 | Tiefenbrun et al. | Nov 1995 | A |
5554119 | Harrison et al. | Sep 1996 | A |
5593434 | Williams | Jan 1997 | A |
5618299 | Khosravi et al. | Apr 1997 | A |
5662124 | Wilk | Sep 1997 | A |
5733267 | Del Toro | Mar 1998 | A |
5755682 | Knudson et al. | May 1998 | A |
5758663 | Wilk et al. | Jun 1998 | A |
5800334 | Wilk | Sep 1998 | A |
5807384 | Mueller | Sep 1998 | A |
5810836 | Hussein et al. | Sep 1998 | A |
5824071 | Nelson et al. | Oct 1998 | A |
5830222 | Makower | Nov 1998 | A |
5876373 | Giba et al. | Mar 1999 | A |
5878751 | Hussein et al. | Mar 1999 | A |
5885259 | Berg | Mar 1999 | A |
5908028 | Wilk | Jun 1999 | A |
5908029 | Knudson et al. | Jun 1999 | A |
5922022 | Nash et al. | Jul 1999 | A |
5925012 | Murphy-Chutorian et al. | Jul 1999 | A |
5931848 | Saadat | Aug 1999 | A |
5935161 | Robinson et al. | Aug 1999 | A |
5938632 | Ellis | Aug 1999 | A |
5944019 | Knudson et al. | Aug 1999 | A |
5968064 | Selmon et al. | Oct 1999 | A |
5971911 | Wilk | Oct 1999 | A |
5971993 | Hussein et al. | Oct 1999 | A |
5976155 | Foreman et al. | Nov 1999 | A |
5980533 | Holman | Nov 1999 | A |
5980548 | Evans et al. | Nov 1999 | A |
5984956 | Tweden et al. | Nov 1999 | A |
5997525 | March et al. | Dec 1999 | A |
5999678 | Murphy-Chutorian et al. | Dec 1999 | A |
6004261 | Sinofsky et al. | Dec 1999 | A |
6004347 | McNamara et al. | Dec 1999 | A |
6007543 | Ellis et al. | Dec 1999 | A |
6010449 | Selmon et al. | Jan 2000 | A |
6026814 | LaFontaine et al. | Feb 2000 | A |
6029672 | Vanney et al. | Feb 2000 | A |
6035856 | LaFontaine et al. | Mar 2000 | A |
6036677 | Javier, Jr. et al. | Mar 2000 | A |
6036697 | DiCaprio | Mar 2000 | A |
6045565 | Ellis et al. | Apr 2000 | A |
6053924 | Hussein | Apr 2000 | A |
6053942 | Eno et al. | Apr 2000 | A |
6056743 | Ellis et al. | May 2000 | A |
6067988 | Mueller | May 2000 | A |
6068638 | Makower | May 2000 | A |
6071292 | Makower et al. | Jun 2000 | A |
6076529 | Vanney et al. | Jun 2000 | A |
6080163 | Hussein et al. | Jun 2000 | A |
6080170 | Nash et al. | Jun 2000 | A |
6090063 | Makower et al. | Jul 2000 | A |
6092526 | LaFontaine et al. | Jul 2000 | A |
6093166 | Knudson et al. | Jul 2000 | A |
6093177 | Javier, Jr. et al. | Jul 2000 | A |
6093185 | Ellis et al. | Jul 2000 | A |
6102941 | Tweden et al. | Aug 2000 | A |
6113630 | Vanney et al. | Sep 2000 | A |
6113823 | Eno | Sep 2000 | A |
6120520 | Saadat et al. | Sep 2000 | A |
6123682 | Knudson et al. | Sep 2000 | A |
6126649 | VanTassel et al. | Oct 2000 | A |
6126654 | Giba et al. | Oct 2000 | A |
6132451 | Payne et al. | Oct 2000 | A |
6139541 | Vanney et al. | Oct 2000 | A |
6155264 | Ressemann et al. | Dec 2000 | A |
6155968 | Wilk | Dec 2000 | A |
6156031 | Aita et al. | Dec 2000 | A |
6157852 | Selmon et al. | Dec 2000 | A |
6159225 | Makower | Dec 2000 | A |
6165185 | Shennib et al. | Dec 2000 | A |
6165188 | Saadat et al. | Dec 2000 | A |
6171251 | Mueller et al. | Jan 2001 | B1 |
6182668 | Tweden et al. | Feb 2001 | B1 |
6186972 | Nelson et al. | Feb 2001 | B1 |
6190353 | Makower et al. | Feb 2001 | B1 |
6193726 | Vanney | Feb 2001 | B1 |
6193734 | Bolduc et al. | Feb 2001 | B1 |
D438618 | Solem | Mar 2001 | S |
6196230 | Hall et al. | Mar 2001 | B1 |
6197050 | Eno et al. | Mar 2001 | B1 |
6197324 | Crittenden | Mar 2001 | B1 |
6200311 | Danek et al. | Mar 2001 | B1 |
6203556 | Evans et al. | Mar 2001 | B1 |
6213126 | LaFontaine et al. | Apr 2001 | B1 |
6214041 | Tweden et al. | Apr 2001 | B1 |
6217527 | Selmon et al. | Apr 2001 | B1 |
6217549 | Selmon et al. | Apr 2001 | B1 |
6217575 | DeVore et al. | Apr 2001 | B1 |
6221049 | Selmon et al. | Apr 2001 | B1 |
6223752 | Vanney et al. | May 2001 | B1 |
6224584 | March et al. | May 2001 | B1 |
6231546 | Milo et al. | May 2001 | B1 |
6231551 | Barbut | May 2001 | B1 |
6231587 | Makower | May 2001 | B1 |
6235000 | Milo et al. | May 2001 | B1 |
6237607 | Vanney et al. | May 2001 | B1 |
6238406 | Ellis et al. | May 2001 | B1 |
6241667 | Vetter et al. | Jun 2001 | B1 |
6248112 | Gambale et al. | Jun 2001 | B1 |
6250305 | Tweden | Jun 2001 | B1 |
6251079 | Gambale et al. | Jun 2001 | B1 |
6251104 | Kesten et al. | Jun 2001 | B1 |
6251116 | Shennib et al. | Jun 2001 | B1 |
6251418 | Ahern et al. | Jun 2001 | B1 |
6253768 | Wilk | Jul 2001 | B1 |
6253769 | LaFontaine et al. | Jul 2001 | B1 |
6254564 | Wilk et al. | Jul 2001 | B1 |
6258021 | Wilk | Jul 2001 | B1 |
6258052 | Milo | Jul 2001 | B1 |
6258119 | Hussein et al. | Jul 2001 | B1 |
6261304 | Hall et al. | Jul 2001 | B1 |
6283951 | Flaherty et al. | Sep 2001 | B1 |
6283983 | Makower et al. | Sep 2001 | B1 |
6285903 | Rosenthal et al. | Sep 2001 | B1 |
6287317 | Makower et al. | Sep 2001 | B1 |
6290709 | Ellis et al. | Sep 2001 | B1 |
6290728 | Phelps et al. | Sep 2001 | B1 |
6302685 | Lobel et al. | Oct 2001 | B1 |
6302875 | Makower et al. | Oct 2001 | B1 |
6302892 | Wilk | Oct 2001 | B1 |
6322548 | Payne et al. | Nov 2001 | B1 |
6330884 | Kim | Dec 2001 | B1 |
6344027 | Goll | Feb 2002 | B1 |
6350248 | Knudson et al. | Feb 2002 | B1 |
6352543 | Cole | Mar 2002 | B1 |
6361519 | Knudson et al. | Mar 2002 | B1 |
6363938 | Saadat et al. | Apr 2002 | B2 |
6363939 | Wilk | Apr 2002 | B1 |
6375615 | Flaherty et al. | Apr 2002 | B1 |
6379319 | Garibotto et al. | Apr 2002 | B1 |
6387119 | Wolf et al. | May 2002 | B2 |
6390098 | LaFontaine et al. | May 2002 | B1 |
6395208 | Herweck et al. | May 2002 | B1 |
6402740 | Ellis et al. | Jun 2002 | B1 |
6406488 | Tweden et al. | Jun 2002 | B1 |
6406491 | Vanney | Jun 2002 | B1 |
6409697 | Eno et al. | Jun 2002 | B2 |
6409751 | Hall et al. | Jun 2002 | B1 |
6416490 | Ellis et al. | Jul 2002 | B1 |
6423089 | Gingras et al. | Jul 2002 | B1 |
6432119 | Saadat | Aug 2002 | B1 |
6432126 | Gambale et al. | Aug 2002 | B1 |
6432127 | Kim et al. | Aug 2002 | B1 |
6432132 | Cottone et al. | Aug 2002 | B1 |
6443158 | LaFontaine et al. | Sep 2002 | B1 |
6447522 | Gambale et al. | Sep 2002 | B2 |
6447539 | Nelson et al. | Sep 2002 | B1 |
6454760 | Vanney | Sep 2002 | B2 |
6454794 | Knudson et al. | Sep 2002 | B1 |
6458092 | Gambale et al. | Oct 2002 | B1 |
6458140 | Akin et al. | Oct 2002 | B2 |
6458323 | Boekstegers | Oct 2002 | B1 |
6464709 | Shennib et al. | Oct 2002 | B1 |
6475226 | Belef et al. | Nov 2002 | B1 |
6475244 | Herweck et al. | Nov 2002 | B2 |
6482220 | Mueller | Nov 2002 | B1 |
6491689 | Ellis et al. | Dec 2002 | B1 |
6491707 | Makower et al. | Dec 2002 | B2 |
6506408 | Palasis | Jan 2003 | B1 |
6508824 | Flaherty | Jan 2003 | B1 |
6508825 | Selmon et al. | Jan 2003 | B1 |
6511458 | Milo et al. | Jan 2003 | B2 |
6514217 | Selmon et al. | Feb 2003 | B1 |
6514271 | Evans et al. | Feb 2003 | B2 |
6517527 | Gambale et al. | Feb 2003 | B2 |
6517558 | Gittings et al. | Feb 2003 | B2 |
6524323 | Nash et al. | Feb 2003 | B1 |
6524324 | Mueller et al. | Feb 2003 | B1 |
6530914 | Mickley | Mar 2003 | B1 |
6533779 | Kinsella et al. | Mar 2003 | B2 |
6544230 | Flaherty et al. | Apr 2003 | B1 |
6559132 | Holmer | May 2003 | B1 |
6561998 | Roth et al. | May 2003 | B1 |
6565528 | Mueller | May 2003 | B1 |
6565594 | Herweck et al. | May 2003 | B1 |
6569145 | Shmulewitz et al. | May 2003 | B1 |
6569147 | Evans et al. | May 2003 | B1 |
6573311 | Martakos et al. | Jun 2003 | B1 |
6575168 | LaFontaine et al. | Jun 2003 | B2 |
6579311 | Makower | Jun 2003 | B1 |
6582444 | Wilk | Jun 2003 | B2 |
6582463 | Mowry et al. | Jun 2003 | B1 |
6585650 | Solem | Jul 2003 | B1 |
6587718 | Talpade | Jul 2003 | B2 |
6589164 | Flaherty | Jul 2003 | B1 |
6599304 | Selmon et al. | Jul 2003 | B1 |
6602241 | Makower et al. | Aug 2003 | B2 |
6605053 | Kamm et al. | Aug 2003 | B1 |
6605113 | Wilk | Aug 2003 | B2 |
6610100 | Phelps et al. | Aug 2003 | B2 |
6613026 | Palasis et al. | Sep 2003 | B1 |
6613081 | Kim et al. | Sep 2003 | B2 |
6616626 | Crank et al. | Sep 2003 | B2 |
6616675 | Evard et al. | Sep 2003 | B1 |
6635214 | Rapacki et al. | Oct 2003 | B2 |
6638237 | Guiles et al. | Oct 2003 | B1 |
6638247 | Selmon et al. | Oct 2003 | B1 |
6638293 | Makower et al. | Oct 2003 | B1 |
6641610 | Wolf et al. | Nov 2003 | B2 |
6651670 | Rapacki et al. | Nov 2003 | B2 |
6652540 | Cole et al. | Nov 2003 | B1 |
6652546 | Nash et al. | Nov 2003 | B1 |
6655386 | Makower et al. | Dec 2003 | B1 |
6660003 | DeVore et al. | Dec 2003 | B1 |
6660024 | Flaherty et al. | Dec 2003 | B1 |
6669691 | Taimisto | Dec 2003 | B1 |
6669709 | Cohn et al. | Dec 2003 | B1 |
6685648 | Flaherty et al. | Feb 2004 | B2 |
6685716 | Flaherty et al. | Feb 2004 | B1 |
6694983 | Wolf et al. | Feb 2004 | B2 |
6709425 | Gambale et al. | Mar 2004 | B2 |
6709427 | Nash et al. | Mar 2004 | B1 |
6709444 | Makower | Mar 2004 | B1 |
6719770 | Laufer et al. | Apr 2004 | B2 |
20010000041 | Selmon et al. | Mar 2001 | A1 |
20010003985 | Lafontaine et al. | Jun 2001 | A1 |
20010004683 | Gambale et al. | Jun 2001 | A1 |
20010004690 | Gambale et al. | Jun 2001 | A1 |
20010004699 | Gittings et al. | Jun 2001 | A1 |
20010008969 | Evans et al. | Jul 2001 | A1 |
20010012924 | Milo et al. | Aug 2001 | A1 |
20010012948 | Vanney | Aug 2001 | A1 |
20010014813 | Saadat et al. | Aug 2001 | A1 |
20010016700 | Eno et al. | Aug 2001 | A1 |
20010018596 | Selmon et al. | Aug 2001 | A1 |
20010020172 | Selmon et al. | Sep 2001 | A1 |
20010025643 | Foley | Oct 2001 | A1 |
20010027287 | Shmulewitz et al. | Oct 2001 | A1 |
20010029385 | Shennib et al. | Oct 2001 | A1 |
20010034547 | Hall et al. | Oct 2001 | A1 |
20010037117 | Gambale et al. | Nov 2001 | A1 |
20010037149 | Wilk | Nov 2001 | A1 |
20010039426 | Makower et al. | Nov 2001 | A1 |
20010039445 | Hall et al. | Nov 2001 | A1 |
20010041902 | Lepulu et al. | Nov 2001 | A1 |
20010044631 | Akin et al. | Nov 2001 | A1 |
20010047165 | Makower et al. | Nov 2001 | A1 |
20010047197 | Foley | Nov 2001 | A1 |
20010049523 | DeVore et al. | Dec 2001 | A1 |
20010053932 | Phleps et al. | Dec 2001 | A1 |
20020002349 | Flaherty et al. | Jan 2002 | A1 |
20020004662 | Wilk | Jan 2002 | A1 |
20020004663 | Gittings et al. | Jan 2002 | A1 |
20020007138 | Wilk et al. | Jan 2002 | A1 |
20020029079 | Kim et al. | Mar 2002 | A1 |
20020032476 | Gambale et al. | Mar 2002 | A1 |
20020032478 | Boekstegers et al. | Mar 2002 | A1 |
20020033180 | Solem | Mar 2002 | A1 |
20020045928 | Boekstegers | Apr 2002 | A1 |
20020049486 | Knudson et al. | Apr 2002 | A1 |
20020049495 | Kutryk et al. | Apr 2002 | A1 |
20020058897 | Renati | May 2002 | A1 |
20020062146 | Makiwer et al. | May 2002 | A1 |
20020065478 | Knudson et al. | May 2002 | A1 |
20020072699 | Knudson et al. | Jun 2002 | A1 |
20020072758 | Reo et al. | Jun 2002 | A1 |
20020077566 | Laroya et al. | Jun 2002 | A1 |
20020077654 | Javier, Jr. et al. | Jun 2002 | A1 |
20020082546 | Crank et al. | Jun 2002 | A1 |
20020092535 | Wilk | Jul 2002 | A1 |
20020092536 | LaFontaine et al. | Jul 2002 | A1 |
20020095110 | Vanney et al. | Jul 2002 | A1 |
20020095111 | Tweden et al. | Jul 2002 | A1 |
20020095206 | Addonizio et al. | Jul 2002 | A1 |
20020099392 | Mowry et al. | Jul 2002 | A1 |
20020100484 | Hall et al. | Aug 2002 | A1 |
20020103459 | Sparks et al. | Aug 2002 | A1 |
20020103495 | Cole | Aug 2002 | A1 |
20020103534 | Vanney et al. | Aug 2002 | A1 |
20020111672 | Kim et al. | Aug 2002 | A1 |
20020123698 | Garibotto et al. | Sep 2002 | A1 |
20020138087 | Shennib et al. | Sep 2002 | A1 |
20020143285 | Eno et al. | Oct 2002 | A1 |
20020143289 | Ellis et al. | Oct 2002 | A1 |
20020143347 | Cole et al. | Oct 2002 | A1 |
20020144696 | Sharkawry et al. | Oct 2002 | A1 |
20020161383 | Akin et al. | Oct 2002 | A1 |
20020161424 | Rapacki et al. | Oct 2002 | A1 |
20020165479 | Wilk | Nov 2002 | A1 |
20020165606 | Wolf et al. | Nov 2002 | A1 |
20020179098 | Makower et al. | Dec 2002 | A1 |
20020183716 | Herweck et al. | Dec 2002 | A1 |
20020193782 | Ellis et al. | Dec 2002 | A1 |
20030015816 | Rapacki et al. | Jan 2003 | A1 |
20030018379 | Knudson et al. | Jan 2003 | A1 |
20030044315 | Boekstegers | Mar 2003 | A1 |
20030045828 | Wilk | Mar 2003 | A1 |
20030055371 | Wilk et al. | Mar 2003 | A1 |
20030062650 | Martakos et al. | Apr 2003 | A1 |
20030073973 | Evans et al. | Apr 2003 | A1 |
20030078561 | Gambale et al. | Apr 2003 | A1 |
20030078562 | Makower et al. | Apr 2003 | A1 |
20030097172 | Shalev et al. | May 2003 | A1 |
20030100920 | Akin et al. | May 2003 | A1 |
20030105514 | Phelps et al. | Jun 2003 | A1 |
20030114872 | Mueller et al. | Jun 2003 | A1 |
20030120195 | Milo et al. | Jun 2003 | A1 |
20030120259 | Mickley | Jun 2003 | A1 |
20030149474 | Becker | Aug 2003 | A1 |
20030158573 | Gittings et al. | Aug 2003 | A1 |
20030181938 | Roth et al. | Sep 2003 | A1 |
20030191449 | Nash et al. | Oct 2003 | A1 |
20030195457 | LaFontaine et al. | Oct 2003 | A1 |
20030195458 | Phelps et al. | Oct 2003 | A1 |
20030195606 | Davidson et al. | Oct 2003 | A1 |
20030204160 | Kamm et al. | Oct 2003 | A1 |
20030212413 | Wilk | Nov 2003 | A1 |
20030216679 | Wolf et al. | Nov 2003 | A1 |
20030229366 | Reggie et al. | Dec 2003 | A1 |
20030236542 | Makower | Dec 2003 | A1 |
20040006298 | Wilk | Jan 2004 | A1 |
20040006301 | Sell et al. | Jan 2004 | A1 |
20040015225 | Kim et al. | Jan 2004 | A1 |
20040019348 | Stevens et al. | Jan 2004 | A1 |
20040044392 | Von Oepen | Mar 2004 | A1 |
20040059280 | Makower et al. | Mar 2004 | A1 |
20040073157 | Knudson et al. | Apr 2004 | A1 |
20040073238 | Makower | Apr 2004 | A1 |
20040077987 | Rapacki et al. | Apr 2004 | A1 |
20040077988 | Tweden et al. | Apr 2004 | A1 |
20040077990 | Knudson et al. | Apr 2004 | A1 |
20040092976 | Mowry et al. | May 2004 | A1 |
Number | Date | Country |
---|---|---|
757647 | Feb 2003 | AU |
0 515 867 | Dec 1992 | EP |
0 732 088 | Sep 1996 | EP |
0 815 798 | Jul 1997 | EP |
0 829 239 | Aug 1997 | EP |
0 792 624 | Sep 1997 | EP |
0 797 957 | Oct 1997 | EP |
0 797 958 | Oct 1997 | EP |
0 799 604 | Oct 1997 | EP |
0 801 928 | Oct 1997 | EP |
0 836 834 | Oct 1997 | EP |
0 876 796 | May 1998 | EP |
0 853 921 | Jul 1998 | EP |
0 858 779 | Aug 1998 | EP |
0 876 803 | Nov 1998 | EP |
0 888 750 | Jan 1999 | EP |
0 895 752 | Feb 1999 | EP |
0 934 728 | Aug 1999 | EP |
1 020 166 | Jul 2000 | EP |
1 027 870 | Aug 2000 | EP |
1 088 564 | Apr 2001 | EP |
1 097 676 | May 2001 | EP |
1 166 721 | Jan 2002 | EP |
0 959 815 | Dec 2002 | EP |
1 112 097 | Jun 2003 | EP |
2 316 322 | Feb 1998 | GB |
2026640 | Jan 1995 | RU |
1754128 | Aug 1992 | SU |
WO 9300868 | Jan 1993 | WO |
WO 9535065 | Dec 1995 | WO |
WO 9600033 | Jan 1996 | WO |
WO 9604854 | Feb 1996 | WO |
WO 9605773 | Feb 1996 | WO |
WO 9632972 | Oct 1996 | WO |
WO 9635469 | Nov 1996 | WO |
WO 9639962 | Dec 1996 | WO |
WO 9639964 | Dec 1996 | WO |
WO 9639965 | Dec 1996 | WO |
WO 9713463 | Apr 1997 | WO |
WO 9713471 | Apr 1997 | WO |
WO 9727893 | Aug 1997 | WO |
WO 9727897 | Aug 1997 | WO |
WO 9727898 | Aug 1997 | WO |
WO 9732551 | Sep 1997 | WO |
WO 9743961 | Nov 1997 | WO |
WO 9803118 | Jan 1998 | WO |
WO 9806356 | Feb 1998 | WO |
WO 9808456 | Mar 1998 | WO |
WO 9810714 | Mar 1998 | WO |
WO 9816161 | Apr 1998 | WO |
WO 9824373 | Jun 1998 | WO |
WO 9825533 | Jun 1998 | WO |
WO 9838916 | Sep 1998 | WO |
WO 9838925 | Sep 1998 | WO |
WO 9838939 | Sep 1998 | WO |
WO 9838941 | Sep 1998 | WO |
WO 9839038 | Sep 1998 | WO |
WO 9846115 | Oct 1998 | WO |
WO 9846119 | Oct 1998 | WO |
WO 9849964 | Nov 1998 | WO |
WO 9857590 | Dec 1998 | WO |
WO 9857591 | Dec 1998 | WO |
WO 9857592 | Dec 1998 | WO |
WO 9907296 | Feb 1999 | WO |
WO 9908624 | Feb 1999 | WO |
WO 9915220 | Apr 1999 | WO |
WO 9917671 | Apr 1999 | WO |
WO 9917683 | Apr 1999 | WO |
WO 9921490 | May 1999 | WO |
WO 9921510 | May 1999 | WO |
WO 9922655 | May 1999 | WO |
WO 9922658 | May 1999 | WO |
WO 9925273 | May 1999 | WO |
WO 9927985 | Jun 1999 | WO |
WO 9935977 | Jul 1999 | WO |
WO 9935979 | Jul 1999 | WO |
WO 9935980 | Jul 1999 | WO |
WO 9936000 | Jul 1999 | WO |
WO 9936001 | Jul 1999 | WO |
WO 9938459 | Aug 1999 | WO |
WO 9940853 | Aug 1999 | WO |
WO 9940868 | Aug 1999 | WO |
WO 9940963 | Aug 1999 | WO |
WO 9944524 | Sep 1999 | WO |
WO 9948545 | Sep 1999 | WO |
WO 9948549 | Sep 1999 | WO |
WO 9949793 | Oct 1999 | WO |
WO 9949910 | Oct 1999 | WO |
WO 9951162 | Oct 1999 | WO |
WO 9953863 | Oct 1999 | WO |
WO 9955406 | Nov 1999 | WO |
WO 9960941 | Dec 1999 | WO |
WO 9962430 | Dec 1999 | WO |
WO 0009195 | Feb 2000 | WO |
WO 0012029 | Mar 2000 | WO |
WO 0013722 | Mar 2000 | WO |
WO 0015146 | Mar 2000 | WO |
WO 0015147 | Mar 2000 | WO |
WO 0015148 | Mar 2000 | WO |
WO 0015149 | Mar 2000 | WO |
WO 0015275 | Mar 2000 | WO |
WO 0018302 | Apr 2000 | WO |
WO 0018323 | Apr 2000 | WO |
WO 0018325 | Apr 2000 | WO |
WO 0018326 | Apr 2000 | WO |
WO 0018331 | Apr 2000 | WO |
WO 0018462 | Apr 2000 | WO |
WO 0021436 | Apr 2000 | WO |
WO 0021461 | Apr 2000 | WO |
WO 0021463 | Apr 2000 | WO |
WO 0024449 | May 2000 | WO |
WO 0033725 | Jun 2000 | WO |
WO 0035376 | Jun 2000 | WO |
WO 0036997 | Jun 2000 | WO |
WO 0041632 | Jul 2000 | WO |
WO 0041633 | Jul 2000 | WO |
WO 0043051 | Jul 2000 | WO |
WO 0045711 | Aug 2000 | WO |
WO 0045886 | Aug 2000 | WO |
WO 0049952 | Aug 2000 | WO |
WO 0049954 | Aug 2000 | WO |
WO 0049956 | Aug 2000 | WO |
WO 0054660 | Sep 2000 | WO |
WO 0054661 | Sep 2000 | WO |
WO 0056224 | Sep 2000 | WO |
WO 0056225 | Sep 2000 | WO |
WO 0056387 | Sep 2000 | WO |
WO 0066007 | Nov 2000 | WO |
WO 0066009 | Nov 2000 | WO |
WO 0066035 | Nov 2000 | WO |
WO 0069345 | Nov 2000 | WO |
WO 0069504 | Nov 2000 | WO |
WO 0071195 | Nov 2000 | WO |
WO 0108566 | Feb 2001 | WO |
WO 0108602 | Feb 2001 | WO |
WO 0110340 | Feb 2001 | WO |
WO 0110341 | Feb 2001 | WO |
WO 0110347 | Feb 2001 | WO |
WO 0110348 | Feb 2001 | WO |
WO 0110349 | Feb 2001 | WO |
WO 0110350 | Feb 2001 | WO |
WO 0117440 | Mar 2001 | WO |
WO 0117456 | Mar 2001 | WO |
WO 0123016 | Apr 2001 | WO |
WO 0141657 | Jun 2001 | WO |
WO 0149187 | Jul 2001 | WO |
WO 0168158 | Sep 2001 | WO |
WO 0170133 | Sep 2001 | WO |
WO 0172239 | Oct 2001 | WO |
WO 0178801 | Oct 2001 | WO |
WO 0182803 | Nov 2001 | WO |
WO 0182837 | Nov 2001 | WO |
WO 02011647 | Feb 2002 | WO |
WO 02011807 | Feb 2002 | WO |
WO 02013698 | Feb 2002 | WO |
WO 02013699 | Feb 2002 | WO |
WO 02013703 | Feb 2002 | WO |
WO 02013704 | Feb 2002 | WO |
WO 02024108 | Mar 2002 | WO |
WO 02024247 | Mar 2002 | WO |
WO 02024248 | Mar 2002 | WO |
WO 02026310 | Apr 2002 | WO |
WO 02026462 | Apr 2002 | WO |
WO 02030325 | Apr 2002 | WO |
WO 02030326 | Apr 2002 | WO |
WO 02030330 | Apr 2002 | WO |
WO 02032330 | Apr 2002 | WO |
WO 02034323 | May 2002 | WO |
WO 02045598 | Jun 2002 | WO |
WO 02049695 | Jun 2002 | WO |
WO 02056937 | Jul 2002 | WO |
WO 02058567 | Aug 2002 | WO |
WO 03008005 | Jan 2003 | WO |
WO 03017870 | Mar 2003 | WO |
Number | Date | Country | |
---|---|---|---|
20020099404 A1 | Jul 2002 | US |